Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: The role of natalizumab

Subrata Ghosh

doi:10.1517/eobt.3.6.995.21264

Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: The role of natalizumab

Subrata Ghosh

Imperial College Healthcare NHS Trust

Research output: Contribution to journal › Review article › peer-review

Abstract

Lymphocyte infiltration into the intestinal tract in Crohn's disease is mediated by the interaction between α₄ integrin, expressed on lymphocytes, and its ligand mucosal vascular addressin cell-adhesion molecule-1 (MADCAM-1), expressed on the endothelial cells of the microvasculature in inflamed intestinal tract. Natalizumab, a recombinant, humanised monoclonal antibody against α₄ integrin was effective in Crohn's disease in a Phase II, randomised, controlled trial. The highest response rate and remission rates were 71 and 44% at 6 weeks, respectively, after two infusions of 3 mg of natalizumab administered 4 weeks apart. Natalizumab was well-tolerated in this study. The Phase III trial results are awaited.

Original language	English
Pages (from-to)	995-1000
Number of pages	6
Journal	Expert Opinion on Biological Therapy
Volume	3
Issue number	6
DOIs	https://doi.org/10.1517/eobt.3.6.995.21264
Publication status	Published - Sep 2003
Externally published	Yes

Keywords

α integrin
Crohn's disease
MADCAM-1
Natalizumab

Access to Document

10.1517/eobt.3.6.995.21264

Cite this

@article{67ef5fda2d3841a480304356942492d4,

title = "Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: The role of natalizumab",

abstract = "Lymphocyte infiltration into the intestinal tract in Crohn's disease is mediated by the interaction between α4 integrin, expressed on lymphocytes, and its ligand mucosal vascular addressin cell-adhesion molecule-1 (MADCAM-1), expressed on the endothelial cells of the microvasculature in inflamed intestinal tract. Natalizumab, a recombinant, humanised monoclonal antibody against α4 integrin was effective in Crohn's disease in a Phase II, randomised, controlled trial. The highest response rate and remission rates were 71 and 44\% at 6 weeks, respectively, after two infusions of 3 mg of natalizumab administered 4 weeks apart. Natalizumab was well-tolerated in this study. The Phase III trial results are awaited.",

keywords = "α integrin, Crohn's disease, MADCAM-1, Natalizumab",

author = "Subrata Ghosh",

year = "2003",

month = sep,

doi = "10.1517/eobt.3.6.995.21264",

language = "English",

volume = "3",

pages = "995--1000",

journal = "Expert Opinion on Biological Therapy",

issn = "1471-2598",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease

T2 - The role of natalizumab

AU - Ghosh, Subrata

PY - 2003/9

Y1 - 2003/9

N2 - Lymphocyte infiltration into the intestinal tract in Crohn's disease is mediated by the interaction between α4 integrin, expressed on lymphocytes, and its ligand mucosal vascular addressin cell-adhesion molecule-1 (MADCAM-1), expressed on the endothelial cells of the microvasculature in inflamed intestinal tract. Natalizumab, a recombinant, humanised monoclonal antibody against α4 integrin was effective in Crohn's disease in a Phase II, randomised, controlled trial. The highest response rate and remission rates were 71 and 44% at 6 weeks, respectively, after two infusions of 3 mg of natalizumab administered 4 weeks apart. Natalizumab was well-tolerated in this study. The Phase III trial results are awaited.

AB - Lymphocyte infiltration into the intestinal tract in Crohn's disease is mediated by the interaction between α4 integrin, expressed on lymphocytes, and its ligand mucosal vascular addressin cell-adhesion molecule-1 (MADCAM-1), expressed on the endothelial cells of the microvasculature in inflamed intestinal tract. Natalizumab, a recombinant, humanised monoclonal antibody against α4 integrin was effective in Crohn's disease in a Phase II, randomised, controlled trial. The highest response rate and remission rates were 71 and 44% at 6 weeks, respectively, after two infusions of 3 mg of natalizumab administered 4 weeks apart. Natalizumab was well-tolerated in this study. The Phase III trial results are awaited.

KW - α integrin

KW - Crohn's disease

KW - MADCAM-1

KW - Natalizumab

UR - https://www.scopus.com/pages/publications/0041334132

U2 - 10.1517/eobt.3.6.995.21264

DO - 10.1517/eobt.3.6.995.21264

M3 - Review article

C2 - 12943458

AN - SCOPUS:0041334132

SN - 1471-2598

VL - 3

SP - 995

EP - 1000

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

IS - 6

ER -

Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: The role of natalizumab

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this